Alpha-9 Oncology | Radiopharmaceuticals | Cancer Therapy

Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma. BOSTON, Mass. and VANCOUVER, British …

CouponFollow Extension

$175
OFF

Alpha-9 Oncology Secures $175M Series C To Drive …

4 weeks from now

Boston, MA and Vancouver, Canada, October 23, 2024 (PRNewswire) -- Alpha-9 Oncology has raised $175 million in Series C funding to advance its radiopharmaceutical pipeline for cancer …

jacobsmgt.com

$175
OFF

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed …

4 weeks from now

Oct 23, 2024 · Alpha-9 Oncology Inc. (Alpha-9 or the Company), a clinical stage company developing radiopharmaceuticals to meaningfully improve the treatment of people living with …

yahoo.com

$175
OFF

Radiopharma Startup Alpha-9 Nets $175M Series C

4 weeks from now

Oct 24, 2024 · In the latest deal for the red-hot radiopharmaceutical field, Alpha-9 Oncology announced an oversubscribed $175 million series C financing to support advancement of its …

insideprecisionmedicine.com

FAQs about Alpha-9 Oncology | Radiopharmaceuticals | Cancer Therapy Coupon?

What is alpha-9 oncology?

About Alpha-9 Alpha-9 Oncology is a clinical stage radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. ...

Is alpha-9 a good radiopharmaceutical company?

"Over the last few years, Alpha-9 has built a leading radiopharmaceutical company with a deep pipeline and robust infrastructure," said Alpha-9 CEO, David Hirsch, MD, PhD. "The Series C is an exciting, significant milestone for us and will greatly accelerate our growth. ...

What is alpha-9 theranostics?

With roots in UBC research, Alpha-9 Theranostics is developing cancer radiotherapies that target tumours while avoiding healthy tissues. ...

What is alpha-9 pharmaceutical?

Alpha-9 designs each component of the radiopharmaceutical for optimal selectivity, stability and payload delivery. The Alpha-9 approach is rigorous, fast and capital efficient, generating best-in-class compounds for rapid clinical development. "We have been following this space for a long time. ...

What's new at Alpha 9?

"Alpha-9 is developing a differentiated portfolio that includes multiple radiopharmaceuticals with first-in-class and best-in-class potential," said Shelley Chu, head of Lightspeed Venture Partners' healthcare team. "We are impressed with the team's progress to date and are proud to support the advancement of these programs." ...

How does alpha-9 work?

Alpha-9 designs each component for optimal selectivity, radiation delivery, and stability. The binder targets cell surface proteins on cancer cells. There are many classes of binders – for example antibodies, small molecules, or peptides. Alpha-9’s initial focus is on peptides and peptide derivatives. The linker connects the binder to the chelator. ...